Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardio Diagnostics Holdings (CDIO) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Cardio Diagnostics Holdings (CDIO) over the last 5 years, with Q3 2025 value amounting to -$1.6 million.

  • Cardio Diagnostics Holdings' Free Cash Flow fell 3181.82% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year increase of 143.23%. This contributed to the annual value of -$5.2 million for FY2024, which is 1664.53% up from last year.
  • Per Cardio Diagnostics Holdings' latest filing, its Free Cash Flow stood at -$1.6 million for Q3 2025, which was down 3181.82% from -$1.6 million recorded in Q2 2025.
  • Cardio Diagnostics Holdings' Free Cash Flow's 5-year high stood at -$174.0 during Q3 2021, with a 5-year trough of -$3.3 million in Q4 2022.
  • For the 5-year period, Cardio Diagnostics Holdings' Free Cash Flow averaged around -$1.3 million, with its median value being -$1.4 million (2024).
  • As far as peak fluctuations go, Cardio Diagnostics Holdings' Free Cash Flow tumbled by 79865919.54% in 2022, and later surged by 3719.74% in 2024.
  • Over the past 5 years, Cardio Diagnostics Holdings' Free Cash Flow (Quarter) stood at -$300944.0 in 2021, then crashed by 999.52% to -$3.3 million in 2022, then soared by 32.83% to -$2.2 million in 2023, then soared by 37.2% to -$1.4 million in 2024, then fell by 11.48% to -$1.6 million in 2025.
  • Its last three reported values are -$1.6 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.4 million during Q1 2025.